scPharmaceuticals, Inc., a Lexington, Mass.-based biopharmaceutical company developing pharmaceutical products for subcutaneous delivery, closed a $16.0m Series A venture financing.
The round was co-led by 5AM Ventures and Lundbeckfond Ventures.
The company intends to use the funds to further develop its first two pharmaceutical products and its associated drug delivery technology.
Led by Bertram Pitt, MD, Professor of Medicine Emeritus at the University of Michigan, and Pieter Muntendam, MD, President, CEO, scPharmaceuticals is developing:
– a novel drug-device combination product based on the active ingredient furosemide, allowing for subcutaneous delivery, and
– a new drug-device combination product of a cephalosporin antibiotic, currently only available for intramuscular and intravenous administration.